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A B S T R A C T
Background
There is inconclusive evidence from observational studies to suggest that people who eat a diet rich in antioxidant vitamins (carotenoids,
vitamins C and E) or minerals (selenium and zinc) may be less likely to develop age-related macular degeneration (AMD).
Objectives
To examine the evidence as to whether or not taking antioxidant vitamin or mineral supplements prevents the development of AMD.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2011, Issue
12), MEDLINE (January 1950 to January 2012), EMBASE (January 1980 to January 2012), Open Grey (System for Information on
Grey Literature in Europe) (www.opengrey.eu/), themetaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), Clinical-
Trials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/
en). There were no date or language restrictions in the electronic searches for trials. The electronic databases were last searched on 26
January 2012.
Selection criteria
We included all randomised controlled trials (RCTs) comparing an antioxidant vitamin and/or mineral supplement (alone or in
combination) to control.
Data collection and analysis
Both review authors independently assessed risk of bias in the included studies and extracted data. One author entered data into
RevMan 5 and the other author checked the data entry. We pooled data using a fixed-effect model.
Main results
We included four RCTs in this review; 62,520 people were included in the analyses. The trials were conducted in Australia, Finland
and the USA and investigated vitamin E and beta-carotene supplements. Overall the quality of the evidence was high. People who took
these supplements were not at decreased (or increased) risk of developing AMD. The pooled risk ratio for any antioxidant supplement
in the prevention of any AMD was 0.98 (95% confidence interval 0.89 to 1.08) and for advanced AMD was 1.05 (95% CI 0.80 to
1.39). Similar results were seen when the analyses were restricted to beta-carotene and alpha-tocopherol alone.
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Authors’ conclusions
There is accumulating evidence that taking vitamin E or beta-carotene supplements will not prevent or delay the onset of AMD. There
is no evidence with respect to other antioxidant supplements, such as vitamin C, lutein and zeaxanthin, or any of the commonly
marketed multivitamin combinations. Although generally regarded as safe, vitamin supplements may have harmful effects and clear
evidence of benefit is needed before they can be recommended. People with AMD should see the related Cochrane review ’Antioxidant
vitamin and mineral supplements for slowing the progression of age-related macular degeneration’ written by the same review team.
P L A I N L A N G U A G E S U M M A R Y
Antioxidant vitamins and mineral supplements to prevent the development of age-related macular degeneration
Age-related macular degeneration (AMD) is a condition affecting the central area of the retina (back of the eye). The retina can
deteriorate with age and some people get lesions that can lead to loss of central vision. Some studies have suggested that people who
eat a diet rich in antioxidant vitamins (carotenoids, vitamins C and E) or minerals (selenium and zinc) may be less likely to get AMD.
The authors identified four large, high-quality randomised controlled trials which included 62,520 people. The trials were conducted
in Australia, Finland and the USA and investigated the effects of vitamin E and beta-carotene supplementation. These trials provide
evidence that taking vitamin E and beta-carotene supplements is unlikely to prevent the onset of AMD. There was no evidence for
other antioxidant supplements and commonly marketed combinations. Although generally regarded as safe, vitamin supplements may
have harmful effects and clear evidence of benefit is needed before they can be recommended.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antioxidant supplement compared with placebo for prevention of AM D
Patient or population: general population
Settings: community
Intervention: vitamin E
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Antioxidant supple-
mentation
Any AM D 180 per 1000 181 per 1000
(159 to 204)
RR 0.97 (0.85 to 1.09) 40,887
(4)
⊕⊕⊕⊕
high
Advanced AM D 6 per 1000 8 per 1000
(5 to 13)
RR 1.34 (0.84 to 2.14) 40,887
(4)
⊕⊕⊕⊕
high
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
AM D: age-related macular degenerat ion; CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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B A C K G R O U N D
Description of the condition
Age-relatedmacular degeneration (AMD) is a disease affecting the
central area of the retina (macula). In the early stages of the dis-
ease lipid material accumulates in deposits underneath the retinal
pigment epithelium. These deposits are known as drusen, and can
be seen as pale yellow spots on the retina. The pigment of the reti-
nal pigment epithelium may become disturbed, with areas of hy-
perpigmentation and hypopigmentation. In the later stages of the
disease, the retinal pigment epithelium may atrophy completely.
This loss can occur in small focal areas or can be widespread (ge-
ographic). In some cases, new blood vessels grow under the reti-
nal pigment epithelium and occasionally into the subretinal space
(exudative or neovascular). Haemorrhage can occur which often
results in increased scarring of the retina.
The early stages of the disease are in general asymptomatic. In the
later stages there may be considerable distortion within the central
visual field leading to a complete loss of central visual function.
Population-based studies suggest that, in people 65 years andolder,
approximately 5% have advanced AMD (Owen 2012). It is the
most common cause of blindness and visual impairment in indus-
trialised countries. In the UK for example, over 30,000 people are
registered as blind or partially sighted annually, half of whom have
lost their vision due to macular degeneration (Bunce 2006).
Description of the intervention
Photoreceptors in the retina are subject to oxidative stress through-
out life due to combined exposures to light and oxygen. It has
been proposed that antioxidants may prevent cellular damage in
the retina by reacting with free radicals produced in the process of
light absorption (Christen 1996).
There are a number of non-experimental studies that have exam-
ined the possible association between antioxidant micronutrients
and AMD, although few studies have examined supplementation
specifically (Chong 2007; Evans 2001). Data on vitamin intake
in observational studies should be considered cautiously as people
who have a diet rich in antioxidant vitamins and minerals, or who
choose to take supplements regularly, are different in many ways
from those who do not; these differences may not be adequately
controlled by statistical analysis. The results of these observational
studies have been inconclusive.
How the intervention might work
The underlying theory is that antioxidant vitamin and mineral
supplements will protect the retina against oxidative stress and that
this protection will delay the onset of AMD.
Why it is important to do this review
Antioxidant vitamin and mineral supplements are increasingly be-
ing marketed for use in age-related eye disease, including AMD.
The aimof this reviewwas to examine the evidence as towhether or
not taking vitamin or mineral supplements prevents the develop-
ment of AMD. See also the related Cochrane review ’Antioxidant
vitamin and mineral supplements for slowing the progression of
AMD’ which considers whether supplementation for people with
AMD slows down the progression of the disease (Evans 2006).
O B J E C T I V E S
To determine whether antioxidant vitamin and/or mineral sup-
plementation prevents the development of AMD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) comparing an-
tioxidant vitamin and/or mineral supplementation (alone or in
combination) to control.
Types of participants
Participants in the trials were people in the general population,
with or without diseases other than AMD. We excluded trials in
which the participants were exclusively people with AMD. These
trials are considered in a separate Cochrane review examining the
effect of supplementation on progression of the disease (Evans
2006).
Types of interventions
Antioxidants were defined as any vitamin or mineral which is
known to have antioxidant properties in vivo or which is known
to be an important component of an antioxidant enzyme present
in the retina. We considered the following: vitamin C, vitamin E,
carotenoids (including themacula pigment carotenoids lutein and
zeaxanthin), selenium and zinc.
Types of outcome measures
The following outcomes were used:
1. number of participants developing AMD;
2. number of participants with visual loss due to AMD;
3. quality of life measures;
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4. any adverse outcomes reported.
We used the following definitions:
AMD: this was taken as defined by trial investigators. It is com-
monly defined as: in the macular area 3000 microns diameter
from fovea: drusen with or without pigmentary abnormalities or
geographic atrophy or characteristic choroidal neovascularisation
with no other cause. Where possible, we have used the Age-Re-
lated Eye Disease Study System for classifying age-related macular
degeneration (AREDS 2001b). In particular, the term ’advanced
AMD’ refers to geographic atrophy or neovascular AMD.
Visual loss: any well-defined outcome based on visual acuity was
used depending on the way in which authors presented trial data.
Quality of life: any validated measurement scale which aims to
measure the impact of visual function loss on quality of life of
participants.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) 2011, Issue 12, part of The Cochrane Library.
www.thecochranelibrary.com (accessed 26 January 2012), MED-
LINE (January 1950 to January 2012), EMBASE (January 1980
to January 2012), Open Grey (System for Information on Grey
Literature in Europe) (www.opengrey.eu/), the metaRegister of
Controlled Trials (mRCT) (www.controlled-trials.com), Clinical-
Trials.gov (www.clinicaltrials.gov) and the WHO International
Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/
search/en). There were no language or date restrictions in the
search for trials. The electronic databases were last searched on 26
January 2012.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1),MEDLINE (Appendix 2), EMBASE (Appendix 3),
OpenGrey (Appendix 5),mRCT (Appendix 6), ClinicalTrials.gov
(Appendix 7) and the ICTRP (Appendix 8).
For the update in 2012 we specifically looked for adverse effects
using a simple search aimed to identify systematic reviews of ad-
verse effects of vitamin supplements, see Appendix (Appendix 9)
for search strategy.
Searching other resources
We searched the Science Citation Index and the reference lists of
reports of trials that were selected for inclusion. We contacted the
investigators of included and excluded trials to ask if they knew of
any other relevant published or unpublished trials.
Data collection and analysis
Selection of studies
Our initial searches identified all trials of antioxidant supplements
and therefore generated many citations. Each review author as-
sessed half of the titles and abstracts resulting from the searches
and selected studies according to the definitions in the ’Criteria
for considering studies for this review’. To check that we were con-
sistent, we both assessed a subset of 100 records and compared re-
sults. We obtained full copies of all reports referring to controlled
trials that definitely or potentially met the inclusion criteria. We
assessed the full copies and selected studies according to the in-
clusion criteria. We wrote to authors of trials for which there were
no published outcome data on AMD to ask whether they had
collected any data on eye disease outcomes.
As none of the trials responded positively, i.e. gave us unpublished
data on AMD, for further updates of this review we only consid-
ered trials with published data on AMD.
In updates to this review, both authors went through the titles and
abstracts resulting from the searches independently and resolved
disagreements by discussion.
Data extraction and management
We extracted data using methods forms developed by the
Cochrane Eyes and Vision Group (http://eyes.cochrane.org/
resources-review-authors). We extracted data independently and
resolved disagreements by discussion. One author cut and pasted
the data into RevMan 5 (Review Manager 2011) and the other
author checked that this had been done correctly.
Assessment of risk of bias in included studies
Two authors independently assessed risk of bias using the
Cochrane Collaboration’s tool for assessing risk of bias as described
in Chapter 8 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). We resolved disagreements by dis-
cussion. We contacted trial authors for clarification on any param-
eter graded as ’unclear’. The review authors were not masked to
any trial details.
Measures of treatment effect
Ourmeasure of treatment effect was the risk ratio for dichotomous
outcomes and themean difference for continuous outcomes. Cur-
rently the review only includes analysis of dichotomous outcomes.
Unit of analysis issues
The interventions, by definition, are applied to the person but as
most people have two eyes trials can analyse data from one or both
eyes. The trials included in this review reported the development
of AMD in either eye of the person therefore the unit of analysis
was the same as the unit of randomisation.
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Assessment of heterogeneity
We assessed heterogeneity by visual inspection of the forest plot,
the χ2 test for heterogeneity and the I2 statistic.
Data synthesis
We summarised data using the risk ratio, after testing for hetero-
geneity between trial results using a standard Chi2 test.
Subgroup analysis and investigation of heterogeneity
No subgroup analyses were planned. Only four trials are included
at present which means that it is not possible to investigate het-
erogeneity formally.
Sensitivity analysis
We planned to conduct sensitivity analyses to determine the im-
pact of study quality on effect size. Currently there are four high-
quality trials included in the review and therefore this is not rele-
vant at present.
R E S U L T S
Description of studies
Results of the search
The initial searches resulted in 3178 titles and abstracts. Of these,
208 were reports of potentially eligible trial reports. From these re-
ports we identified seven primary prevention trials of antioxidant
vitamin or mineral supplements (ATBC 1994; CARET; de Klerk
1998; LINXIAN; Nambour 1995; PHS I; WHS). Investigators
from three trials have confirmed that they did not collect data
on AMD (CARET; de Klerk 1998; Nambour 1995). These trials
have been excluded from the review. We did not receive a response
from one trial (LINXIAN) and this trial has been excluded. Three
trials have published data on AMD outcomes (ATBC 1994; PHS
I; WHS) and are included in this review. Search of the National
Eye Institute Clinical Research register identified one further on-
going trial which is collecting information onAMD - theWomen’s
Antioxidant Cardiovascular Study (WACS). There are two trials
that have recruited participants with and without AMD (AREDS;
VECAT). VECAT is included in this review because 82% of par-
ticipants did not have signs of AMD. AREDS is not included in
this review because AMD outcomes for people without AMD at
baseline were not reported; it is included in the Cochrane review
examining the effect of supplementation on progression of the
disease (Evans 2006).
The original search strategy involved identifying all trials of an-
tioxidant interventions and asking trialists if they had collected
data on AMD. We wrote to the authors of 60 trials of antioxidant
interventions in people with diseases other than AMD. We re-
ceived 15 responses and none had collected any relevant data. All
60 trials are shown in the excluded studies section of this review.
As this proved to be an inefficient way of identifying relevant tri-
als, subsequent searches included terms for AMD. Three hundred
and sixty-seven reports of trials were found in May 2002, 343 in
May 2005 and 64 reports in January 2006 but no further trials
were identified that were relevant for inclusion in this review. The
results of the PHS I study were published in 2007.
The searches were repeated in August 2007 in which a total of 129
reports of studies were identified. The Trials Search Co-ordinator
(TSC) scanned the search results and removed 84 references which
were not relevant to the scope of the review. We screened the title
and abstracts of the remaining 45 references and obtained full-text
copies of four reports to assess for potential inclusion in the review.
We identified one new report from the PHS I study to be included
in the review and the three remaining studies were excluded. For
reasons of exclusion, see ’Characteristics of excluded studies’ table.
An update search was done in January 2012 which yielded 477
titles and abstracts. The TSC scanned the search results and re-
moved 206 references which were not relevant to the scope of the
review. We screened the title and abstracts of the remaining 271
references. We rejected 267 abstracts as not eligible for inclusion
in the review. We obtained full-text copies of four reports for fur-
ther examination. One new report from the WHS study has been
included in the review and three other studies were excluded. For
reasons of exclusion, see ’Characteristics of excluded studies’ table.
Included studies
See the ’Characteristics of included studies’ table for more detailed
information.
Types of participants
The studies took place in Australia, USA and Finland. Two studies
recruited men only (ATBC 1994; PHS I), one study recruited
women only (WHS) and one study recruited men and women
(VECAT). People taking part in the trials were identified from the
general population. Participants in PHS I were male physicians
and in WHS were female health professionals. In ATBC 1994,
a random sample of 1035 men aged 65 years or above from the
main study were invited to participate with a response rate of 91%
(941 men). In VECAT, 18% had AMD at baseline.
Types of intervention
In ATBC 1994, the groups received either alpha-tocopherol 50
mg per day alone, beta-carotene 20 mg per day alone, alpha-
tocopherol and beta-carotene or placebo. All formulations were
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coloured with quinoline yellow. Treatment duration was five to
eight years (median 6.1 years). In VECAT, participants were ran-
domised to vitamin E (500 IU a day) or placebo. Supplementation
continued for four years. In PHS I, the groups received aspirin
325 mg every other day, beta-carotene 50 mg every other day, as-
pirin and beta-carotene or placebo. Treatment duration averaged
12 years. In WHS, participants received vitamin E (600 IU on
alternate days) or placebo and were followed up for 10 years.
Types of outcome measures
In ATBC 1994, three photographs of each eye were taken with
a Canon fundus camera at 40 and 60 degree angles on Kodak
Ektachrome 100 ASA slide film. These photographs were graded
by one observer masked to the participant’s treatment group. The
following grades of maculopathy were used: 0 = none; I = dry
maculopathy with hard drusen and/or pigmentary changes; II =
soft macular drusen; III = disciform degeneration; IV = geographic
atrophy.
In PHS I and WHS, AMD was ascertained by self report: “Have
you ever had macular degeneration diagnosed in your right or left
eye?”. If the participant answered yes to this question permission
was gained to contact their ophthalmologist or optometrist and
further details were obtained from the medical records.
In VECAT, photographs were taken with a Nidek 3-DX fundus
camera on Kodachrome 64 ASA colour film. The photographs
were graded at baseline independently by two trained graders.
Early AMD(the primary outcome)was defined as soft drusen (dis-
tinct or indistinct) or pigmentary changes (hyperpigmentation or
hypopigmentation) on photographic grading. On clinical grading
this was large/soft drusen or non-geographical retinal pigment ep-
ithelium atrophy. VECAT used Bailey-Lovie visual acuity charts
#4 and #5 (National Vision Research Institute, Australia).
Excluded studies
See the ’Characteristics of excluded studies’ table for further in-
formation.
Risk of bias in included studies
We considered all four trials to be at low risk of bias (Figure 1;
Figure 2). See ’Risk of bias’ tables for each included study for
details of the assessment.
Figure 1. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
See: Summary of findings for themain comparison Summary of
findings: vitaminE;Summary of findings 2Summary of findings:
beta-carotene
Overall 62,520 participants were included in the analyses of the
four included trials. There were 863 cases of AMD in the antioxi-
dant groups and 732 cases of AMD in the placebo groups (Analysis
1.1). The results of the four studies were reasonably consistent (I
2 = 16%). There was little evidence of any effect of antioxidant
supplementation (RR 0.98, 95% CI 0.89 to 1.08).
Similarly with advanced AMD the trials were consistent (I2 =
0%) and indicate little evidence of any effect of supplementation
(RR 1.05, 95% CI 0.80 to 1.39) (Analysis 1.2). There were fewer
advanced AMD events (110 cases in the antioxidant groups and
97 in the placebo groups).
Similar results were seen for analyses of alpha-tocopherol alone
versus placebo (Analysis 2.1; Analysis 2.2). A total of 40,887 peo-
ple randomised in ATBC, VECAT andWHS resulted in 447 cases
of AMD in the alpha-tocopherol group and 458 in the placebo
group (Analysis 2.1). The trial results were less consistent (I2 =
53%). There was little evidence of any effect of supplementation
with alpha-tocopherol on the incidence of AMD (RR 0.97, 95%
CI 0.85 to 1.09). There were fewer cases of advanced AMD: 42
in the alpha-tocopherol groups and 31 in the placebo (Analysis
2.2). Again there was little evidence of any benefit from supple-
mentation with a pooled RR in the direction of harm 1.34 (95%
CI 0.84 to 2.14).
A total of 21,589 people were randomised into ATBC and PHS
I comparing beta-carotene with placebo (Analysis 3.1; Analysis
3.2). There were 343 cases of AMD in the beta-carotene groups
and 327 in the control groups (Analysis 3.1). The results of the
trials were consistent (I2 = 0%) and did not indicate any benefit of
supplementation (RR 1.03, 95% CI 0.89 to 1.19). There were 65
cases of advanced AMD in the beta-carotene groups and 67 cases
of advanced AMD in the control (Analysis 3.2). Again the results
of the trials were consistent (I2 = 0%) and indicated little effect of
supplementation (RR 0.97, 95% CI 0.69 to 1.36).
Adverse effects
None of the trials included in this review reported eye-related
adverse effects. The main ATBC trial found an increased risk
of lung cancer associated with beta-carotene supplementation
(ATBC 1994), a finding that was repeated in the large CARET
trial (Omenn1996). Beta-carotene supplementation is contraindi-
cated in people who smoke or have been exposed to asbestos. The
AREDS study found an increased risk of hospitalisation for geni-
tourinary conditions in men taking high-dose zinc supplementa-
tion (Johnson 2007) and increased yellowing of the skin (AREDS
2001a).
Huang 2006 did not identify any consistent adverse effects of
mineral and vitamin supplements but only included nine RCTs
in their review. A subsequent Cochrane review including 78 trials
with 296,707 participants concluded “We found no evidence to
support antioxidant supplements for primary or secondary prevention.
Beta-carotene and vitamin E seem to increase mortality, and so may
higher doses of vitamin A” (Bjelakovic 2012).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Antioxidant supplement compared with placebo for prevention of AM D
Patient or population: general population
Settings: community
Intervention: beta-carotene
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Antioxidant supple-
mentation
Any AM D 180 per 1000 193 per 1000
(166 to 223)
RR 1.03 (0.89 to 1.19) 21,589
(3)
⊕⊕⊕⊕
high
Advanced AM D 6 per 1000 6 per 1000
(4 to 8)
RR 0.97 (0.69 to 1.36) 21,589
(3)
⊕⊕⊕⊕
high
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
AM D: age-related macular degenerat ion; CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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D I S C U S S I O N
Summary of main results
This review provides evidence that people who take vitamin E or
beta-carotene supplements do not reduce their risk of developing
AMD (Summary of findings for the main comparison; Summary
of findings 2).
Overall completeness and applicability of
evidence
This review includes four large, high-quality studies which have
randomised over 64,000members of the population to antioxidant
supplementation or placebo. Duration of supplementation has
ranged from four to 12 years.
This review does not provide evidence as to the effects of other
antioxidant vitamin andmineral supplements on the development
of AMD, in particular it does not provide evidence as to the effects
of commonly marketed vitamin combinations.
There are additional ongoing studies, including a further Physi-
cians Health Study (PHS II). In theWomen’s Antioxidant Cardio-
vascular Study 8171 female health professionals who are at high
risk for cardiovascular disease morbidity and mortality are being
randomised using a 2 x 2 x 2 x 2 factorial design to vitamin C,
vitamin E, folate, vitamin B6 and vitamin B12 supplementation
(WACS).
Although generally regarded as safe, antioxidant supplements may
have harmful effects. Beta-carotene increases the risk of lung cancer
and overall there is some evidence of a small increased risk of
mortality in people who take beta-carotene or vitamin E.
Quality of the evidence
Overall the quality of the evidence was considered to be high
(Summary of findings for the main comparison; Summary of
findings 2).
In ATBC 1994 there was no association with the treatment group
and development of early stages of the disease. If anything, there
was a tendency for more cases to be present in the treatment rather
than the placebo group. This was not statistically significant. One
drawback of adding on a maculopathy study to a trial of primary
prevention is that we have no information on maculopathy sta-
tus before supplementation. Therefore we have to assume that (1)
maculopathy was equally distributed across study groups at the
start of the study and (2)most observed events occurred during the
study period. It is likely that this is true for a reasonable propor-
tion of the events as the maculopathy study began eight years after
recruitment for the main trial and randomisation should have en-
sured equal distribution of maculopathy between the two groups.
Supplementation in this study began at age 50 to 69 and lasted five
to eight years. Currently we do not know at what age antioxidant
protectionmay be important. Itmay be that this was too late or too
short a period of supplementation to show an effect. This study
was conducted in Finnishmale smokers andwe have to be cautious
in extrapolating the findings to other geographical areas, to people
in other age groups, to women and to non-smokers. However, the
incidence of AMD, particularly neovascular disease, is likely to be
higher in smokers (Klein 1993) which means that they provide a
good population to demonstrate any potential protective effects
of antioxidant supplementation.
The results of VECAT similarly do not provide evidence of a
benefit of supplementation in people with no or mild/borderline
AMD, although again these studies have been underpowered to
examine late-stage disease.
In the PHS I over 20,000 physicians received supplementation
with beta-carotene over 12 years. There was little evidence of any
benefit of beta-carotene supplementation. AMD was ascertained
bymedical record review and thereforemay have been less accurate.
However, there is no reason to suppose that the ascertainment will
have been different in the treatment and control groups.
The Age-Related Eye Disease Study is not included in this review.
However, there were 2180 people recruited with no or mild/bor-
derline AMD (AREDS 2001a). The study reported no benefit
of the study treatment for these people, however the number of
events was small.
Although the number of people randomised in these studies is
large there is still a degree of uncertainty in the pooled estimates.
In the pooled analyses the risk ratios were largely around the null
value or just above the null value.
Agreements and disagreements with other
studies or reviews
A recent systematic review of observational prospective studies also
found little evidence of a protective effect of dietary antioxidants
(Chong 2007). The only dietary antioxidant for which a reduction
was seen was vitamin E, in contrast to the evidence from the
trials included in this review. It is possible that natural vitamin E
fromdietary sources rather than artificial supplements has different
effects, or alternatively high levels of dietary vitamin E might be a
marker for other nutrients, for example, dietary fatty acids.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is no evidence from randomised controlled trials that
healthy people should take antioxidant vitamin and mineral sup-
plements to prevent or delay the onset of AMD.
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Implications for research
There are a number of unanswered questions in the prevention of
AMD. The hypothesis that antioxidant micronutrients may pro-
tect against the disease is a reasonable one. We do not know at
what stage the protective effect may be important, nor the po-
tential interactions with genetic effects and other risk factors for
the disease such as smoking. The research to date shows that we
cannot extrapolate to taking vitamin supplements without good
evidence of their effectiveness and safety. Further trials are war-
ranted to address this question and the results of ongoing trials are
awaited. The small number of incident events in healthy people
mean that trials need to be very large. Four large primary and sec-
ondary prevention trials in the field of cancer and cardiovascular
disease have added on an examination of eye disease. This would
seem to be a cost-effective way forward in research in this area.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ATBC
Methods Method of allocation: random. Sponsor provided coded capsules.
Masking: participant: yes; provider: yes; outcome: yes
Exclusions after randomisation: no
Losses to follow-up: 31%. Random sample for maculopathy study: 9%.
Unusual study design: 2 x 2 factorial design. Maculopathy add-on random sample in 2
regions
Participants Country: Finland
Number of participants randomised: 29,133. Random sample of 1035 selected for mac-
ulopathy study.
Age: 50 to 69 years in 1984. Maculopathy study 1992/3 in people aged 65 plus.
Sex: Male
Inclusion criteria: 5 or more cigarettes daily
Exclusion criteria: history of cancer or serious disease limiting ability to participate; those
taking supplements vitamin E, A or beta-carotene in excess of predefined doses; those
treated with anticoagulants
Interventions Treatment: 3 regimens: alpha-tocopherol (50 mg), beta-carotene (20 mg) or alpha-to-
copherol and beta-carotene
Control: placebo
Duration: 5 to 8 years (median 6.1)
Outcomes AMD: 4 grades:
Grade I: dry maculopathy with hard drusen and/or pigmentary changes
Grade II: soft macular drusen
Grade III: disciform degeneration
Grade IV: geographic atrophy
Notes Compliance with treatment excellent; 4/5 active participants took more than 95% of
scheduled capsules. Drop-out rate and compliance similar between all 4 groups
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The participants were randomly assigned to
one of four treatment groups: AT alone, AT
and BC, BC alone, or placebo in a complete
2 x 2 factorial design” and “Randomiza-
tion was performed in blocks of eight within
each of the study areas.” The ATBC Cancer
Prevention Study Group. The alpha-toco-
pherol, beta-carotene lung cancer preven-
tion study: design, methods, participant
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ATBC (Continued)
characteristics, and compliance. Annals of
Epidemiology 1994;4: page 1
Allocation concealment (selection bias) Low risk “A coded reserve supply of capsule packs...”
page 3
Not clearly stated that allocation concealed
but the study was described as being “dou-
ble-blind”
Blinding of participants and personnel
(performance bias)
AMD
Low risk “The retinal specialist [...] examined six pho-
tographs (three per eye) of each participant
without knowledge of the subject’s treatment
group” Teikari et al page 226
Blinding of outcome assessment (detection
bias)
AMD
Low risk “The retinal specialist [...] examined six pho-
tographs (three per eye) of each participant
without knowledge of the subject’s treatment
group” Teikari et al page 226
Incomplete outcome data (attrition bias)
All outcomes
Low risk “A total of 941 persons participated (91%)
and non-participation rates were similar
across the intervention groups.” Teikari et al
page 226
Selective reporting (reporting bias) Unclear risk Visual acuity measured but not reported
but as the main results for AMD showed
no difference between groups it is not clear
whether this is an example of selective re-
porting or whether in fact the investiga-
tors considered that visual acuity in this age
group might be attributed to a variety of
causes and therefore was not a relevant out-
come
PHS I
Methods Method of allocation: coded tablets
Masking: participant: yes; provider: yes; outcome: yes
99% follow-up
Unusual study design: 2 x 2 factorial design.
Participants Country: USA
Number randomised: originally 22,071 men were randomised: 11,036 to beta-carotene,
11,035 to beta-carotene placebo
21,142 participants were followed up for at least 7 years and provided information on
diagnoses of AMD made during the first 7 years of the trial
10,585 were in the beta-carotene group and 10,557 were in the placebo group
Age: 40 to 84 years in 1982
Sex: male
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PHS I (Continued)
Inclusion criteria:
Physician aged 40 to 84 years in 1982 with no history of cancer, myocardial infarction,
stroke or transient cerebral ischaemia
Exclusion criteria:personal history of cardiovascular disease or cancer; contraindications
or current use of study medication;
Interventions Treatment:
4 groups:
1. Aspirin 325 mg every other day plus beta-carotene placebo
2. Beta-carotene 50 mg every other day plus aspirin placebo
3. Both active agents
Control:
4. Both placebos
Duration:
Aspirin component terminated early January 1988
Beta-carotene component terminated December 1995. Mean duration 12 years range
(11.6 to 14.2 years)
Outcomes Self report of AMD followed by medical record review and questionnaire to relevant
ophthalmologist
Primary endpoint: visually significantAMD,defined as a self report confirmedbymedical
record evidence of an initial diagnosis after randomisation but before 31 December 1995
with a reduction in best-corrected visual acuity to 20/30 or worse attributable to AMD
Secondary endpoints: AMDwith or without vision loss, composed of all incidence cases
Advanced AMD, encompassed of cases of visually significant AMD with pathological
signs of disciform scar, RPE detachment, geographic atrophy or subretinal neovascular
membrane
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The PHS I was a randomized, double-
masked, placebo controlled trial...” Page 334
Christen et al 2007
“A total of 22,071 physicians were then ran-
domized according to a two-by-two factorial
design, with use of a computer-generated list
of random numbers...” Page 262 New Eng-
land Journal of Medicine 1982
Allocation concealment (selection bias) Low risk “The PHS I was a randomized, double-
masked, placebo controlled trial...” Page 334
Christen et al 2007
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PHS I (Continued)
Blinding of participants and personnel
(performance bias)
AMD
Low risk “The PHS I was a randomized, double-
masked, placebo controlled trial...” Page 334
Christen et al 2007
Although this aspect of the trial was not
well described the placebo control was de-
scribed (placebo and supplement identical
appearance and packaging) and the study
was described as double-blind
Blinding of outcome assessment (detection
bias)
AMD
Low risk “The PHS I was a randomized, double-
masked, placebo controlled trial...” Page 334
Christen et al 2007
Although this aspect of the trial was not
well described the placebo control was de-
scribed and the study was described as dou-
ble-blind. Diagnosis of AMD by self report
based on health questionnaire (confirmed
by ophthalmologist and optometrist). Pa-
tients and researchers unaware of interven-
tion
Incomplete outcome data (attrition bias)
All outcomes
Low risk “At the end of 11 years of follow-up (the last
year completed for all participants), 99.2%
were still providing information on morbid-
ity, and the follow-up for mortality was 99.
9% complete. Eighty percent of participants
in the beta carotene group and in the placebo
group
were still taking the study pills, with a mean
compliance among pill takers of more than
97%. Therefore, even after 11 years, 78% of
the study pills assigned in the beta carotene
group were reported as still being taken. In the
placebo group, 6% of participants reported
taking supplemental beta carotene or vitamin
A.” Christen et al 2007 page 334
Selective reporting (reporting bias) Low risk Reported AMD outcomes as expected
VECAT
Methods Method of allocation: coded bottles
Masking: participant: yes; provider: yes; outcome: yes
Losses to follow-up: not known
Participants Country: Australia
Number of participants randomised: 1204
Age: 55 to 80 years, mean 66
24Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
VECAT (Continued)
Sex: 56% female
Inclusion criteria: lens and retina of at least one eye available for documentation
Exclusion criteria: previous cataract surgery or advanced cataract in both eyes; steroid or
anticoagulation use; serious disease; regular use or sensitivity to vitamin E
Interventions Vitamin E 500 IU per day: natural vitamin E in soybean oil medium
Control: placebo identical in sight, taste and smell
Duration: 4 years
Outcomes 2m logMAR visual acuity; clinical examination; colour stereoscopic fundus photographs
graded using International Grading Scheme
Notes Worse eye used as the study eye
Methodology published but results available from abstract only
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “This random allocation was performed by
using a “permuted blocks” allocation scheme”
Page 2
Allocation concealment (selection bias) Low risk “Study numbers were allocated sequentially
by the study coordinator as participants were
enrolled in the study. Participants were then
randomly allocated to treatment group. The
allocation list was stored at a remote site.”
Page 2
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk “Participants randomly received either 500
IUnatural vitamin E (335mg dá tocopherol)
in a soybean oil suspension encapsulated in
gelatin or a matched placebo capsule contain-
ing only the soybean oil.” [...] “Bulk medi-
cations were dispensed into labelled jars by a
person not involved in the study. Vitamin E
and placebo were dispensed on different days
to avoid confusion. Identical containers were
used. The jars were packed in numerical order
and then dispensed by study personnel. Vita-
min E and placebo capsules were of identical
appearance and taste. Neither study staff nor
examiners or participants were aware of the
treatment allocation, although all knew that
participants would be randomly assigned to
receive either vitamin E or placebo.” Page 2
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VECAT (Continued)
Blinding of participants and personnel
(performance bias)
AMD
Low risk “Participants randomly received either 500
IUnatural vitamin E (335mg dá tocopherol)
in a soybean oil suspension encapsulated in
gelatin or a matched placebo capsule contain-
ing only the soybean oil.” [...] “Bulk medi-
cations were dispensed into labelled jars by a
person not involved in the study. Vitamin E
and placebo were dispensed on different days
to avoid confusion. Identical containers were
used. The jars were packed in numerical order
and then dispensed by study personnel. Vita-
min E and placebo capsules were of identical
appearance and taste. Neither study staff nor
examiners or participants were aware of the
treatment allocation, although all knew that
participants would be randomly assigned to
receive either vitamin E or placebo.” Page 2
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk “Neither study staff nor examiners or partici-
pants were aware of the treatment allocation,
although all knew that participants would be
randomly assigned to receive either vitamin E
or placebo.” Page 2
Blinding of outcome assessment (detection
bias)
AMD
Low risk “Neither study staff nor examiners or partici-
pants were aware of the treatment allocation,
although all knew that participants would be
randomly assigned to receive either vitamin E
or placebo.” Page 2
“At the end of the study we reassessed the ini-
tial and final photographs for any change with
a “side by side” comparison in a masked and
randomised
fashion”. Page 2
Incomplete outcome data (attrition bias)
All outcomes
Low risk “From the 1906 people who were screened by
telephone, 1289 (69%) were examined and
1204 (93%) of these were enrolled and ran-
domised. We excluded 11 participants after
randomisation as they were outside the re-
quired age range at enrolment.” Page 1
“In the vitamin E group eight people were ex-
cluded from final data analysis: six developed
diabetic retinopathy, one had myopic degen-
eration, and one had missing data. Six peo-
ple were excluded from the placebo group: two
developed adult vitelliform macular degener-
ation and four had
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VECAT (Continued)
missing data” Page 3
Figure 3 Page 4 1204 randomised, 11 ex-
cluded after randomisation, 14 excluded
from analysis 8/595 vitamin E group and
6/598 placebo group
Selective reporting (reporting bias) Low risk AMD incidence and progression reported
but no difference between groups; visual
acuity not reported but “Analysis of best
corrected visual acuity and visual function
data showed no differences between the groups
(data not shown).” Page 4. Therefore no ev-
idence that outcomes with “better” results
selectively reported
WHS
Methods Method of allocation:
Masking: participant: yes; provider: yes; outcome: yes
Losses to follow-up: not known
Participants Country: USA
Number of participants randomised: 39,876 women health professionals
Age: 45+
Sex: 100% female
Inclusion/exclusion criteria:
a) Female; (b) aged 45 years or older; (c) postmenopausal or with no intention of becom-
ing pregnant; (d) no reported personal history of cardiovascular disease, cancer (other
than non-melanoma skin cancer), gout, peptic ulcer, chronic renal or liver disease, or
other serious illness precluding participation; (e) no reported history of serious side effects
to the study treatments; (f ) not currently taking aspirin, aspirin containing medication,
or nonsteroidal anti-inflammatory drugs (NSAIDs) more than 1 day per week or, if so
doing, willing to forego use of these medications; (g) not currently taking individual
supplements of vitamin E or beta-carotene more than 1 day per week; (h) not currently
taking anticoagulants or corticosteroids
Interventions Vitamin E (600 IU on alternate days) or placebo
Outcomes Self report and review of medical records
Notes NCT00000161
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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WHS (Continued)
Random sequence generation (selection
bias)
Low risk “The WHS was a randomized, double-
blind, placebo-controlled, 2x2 factorial trial.
..” Page 1163
Allocation concealment (selection bias) Low risk “The WHS was a randomized, double-
blind, placebo-controlled, 2x2 factorial trial.
..” Page 1163
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk “Study medications and end-point ascertain-
ment were continued in a blinded fashion
through the scheduled end of the trial (March
31, 2004).” Ridker et al 2005 page 1294
“Pill taking and end point ascertainment
were continued in blinded fashion through the
scheduled end of the trial onMarch 31, 2004.
Morbidity and mortality follow-up were 97.
2% and 99.4% complete, respectively.” Page
1164
Blinding of participants and personnel
(performance bias)
AMD
Low risk “Study medications and end-point ascertain-
ment were continued in a blinded fashion
through the scheduled end of the trial (March
31, 2004).” Ridker et al 2005 page 1294
“Pill taking and end point ascertainment
were continued in blinded fashion through the
scheduled end of the trial onMarch 31, 2004.
Morbidity and mortality follow-up were 97.
2% and 99.4% complete, respectively.” Page
1164
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk “Study medications and end-point ascertain-
ment were continued in a blinded fashion
through the scheduled end of the trial (March
31, 2004).” Ridker et al 2005 page 1294
“Pill taking and end point ascertainment
were continued in blinded fashion through the
scheduled end of the trial onMarch 31, 2004.
Morbidity and mortality follow-up were 97.
2% and 99.4% complete, respectively.” Page
1164
Blinding of outcome assessment (detection
bias)
AMD
Low risk “Study medications and end-point ascertain-
ment were continued in a blinded fashion
through the scheduled end of the trial (March
31, 2004).” Ridker et al 2005 page 1294
“Pill taking and end point ascertainment
were continued in blinded fashion through the
scheduled end of the trial onMarch 31, 2004.
Morbidity and mortality follow-up were 97.
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WHS (Continued)
2% and 99.4% complete, respectively.” Page
1164
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Compliance (defined as taking at least two
thirds of the study capsules) was 78.9% at 5
years and 71.6% at 10 years, and averaged
75.8% throughout the trial.” Page 1164
“Pill taking and end point ascertainment
were continued in blinded fashion through the
scheduled end of the trial onMarch 31, 2004.
Morbidity and mortality follow-up were 97.
2% and 99.4% complete, respectively.” Page
1164
Follow-up balanced across treatment
groups. See figure 1 page 1164
Selective reporting (reporting bias) Low risk No evidence of selective reporting. The
outcome was limited to the study design
- medical record review. Primary and sec-
ondary outcomes were apparently defined
a priori and were reported
AMD: age-related macular degeneration
ETDRS: Early Treatment Diabetic Retinopathy Study
IU: international units
RPE: retinal pigment epithelium
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
ADSC No published data on age-related macular degeneration. No response from author
Andrews 1969 No published data on age-related macular degeneration. Unable to contact author
AREDS Age-related maculopathy outcomes for people without age-related maculopathy at baseline were not
reported
Benner 1994 No published data on age-related macular degeneration. No response from author
Benton 1995 No data on age-related macular degeneration collected
Blok 1997 No data on age-related macular degeneration collected
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(Continued)
Bogden 1990 No published data on age-related macular degeneration. No response from author
Bone 2010 Biological availability study only
Brewer 1997 No published data on age-related macular degeneration. No response from author
Brown 1998 No published data on age-related macular degeneration. No response from author
Bussey 1982 No published data on age-related macular degeneration. No response from author
Caligiuri 1997 No published data on age-related macular degeneration. No response from author
CARET No data on age-related macular degeneration collected
CARMIS Study on people with AMD (non-advanced AMD) therefore not on prevention in healthy people
CCSG No published data on age-related macular degeneration. No response from author
Chandra 1992 No published data on age-related macular degeneration. No response from author
CHAOS No data on age-related macular degeneration collected
Clausen 1989 No published data on age-related macular degeneration. No response from author
Constans 1996 No published data on age-related macular degeneration. No response from author
Constantino 1988 No data on age-related macular degeneration collected
Cucinotta 1994 No published data on age-related macular degeneration. No response from author
DATATOP No published data on age-related macular degeneration. Unable to contact author
de Klerk 1998 No data on age-related macular degeneration collected
DeCosse 1989 No published data on age-related macular degeneration. No response from author
Dobson 1984 No data on age-related macular degeneration collected
ECP-IM No published data on age-related macular degeneration. No response from author
EUROSCAN No published data on age-related macular degeneration. No response from author
Fairley 1996 No published data on age-related macular degeneration. No response from author
Falsani 2010 Participants had early AMD
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(Continued)
Fontham 1995 No data on age-related macular degeneration collected
Galan 1997 No published data on age-related macular degeneration. No response from author
Garawal 1995 No published data on age-related macular degeneration. No response from author
GISSI No published data on age-related macular degeneration. No response from author
HOPE No data on age-related macular degeneration collected
Johnson 1997 No published data on age-related macular degeneration. No response from author
Jyothirmayi 1996 No published data on age-related macular degeneration. No response from author
Kuklinski 1994 No published data on age-related macular degeneration. No response from author
Kvansakul 2006 No AMD outcomes
Leng 1997 No published data on age-related macular degeneration. Unable to contact author
Li 1992 No published data on age-related macular degeneration. No response from author
LINXIAN No published data on age-related macular degeneration. No response from author
Mayne 1998 No data on age-related macular degeneration collected
McKeown 1988 No data on age-related macular degeneration collected
Meyskens 1994 No published data on age-related macular degeneration. No response from author
Munoz 1987 No published data on age-related macular degeneration. No response from author
Munoz 1996 No published data on age-related macular degeneration. No response from author
Nambour 1995 No follow-up data on age-related macular degeneration collected
NCT00718653 Study of macular pigment only
NCT01208948 No AMD outcomes
Newsome, 2008 Study on people with AMD
NPCSG No published data on age-related macular degeneration. No response from author
Pastorino 1991 No published data on age-related macular degeneration. No response from author
Pemp 2010 Study of ocular blood flow and endothelial function only inmodel of oxidative stress in health volunteers
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(Continued)
Peng 1993 No published data on age-related macular degeneration. No response from author
PPP No published data on age-related macular degeneration. No response from author
PPSG No data on age-related macular degeneration collected
Prasad 1995 No published data on age-related macular degeneration. No response from author
REACT No published data on age-related macular degeneration. No response from author
Recchia 1995 No published data on age-related macular degeneration. No response from author
Rein 2007 Study not a randomised controlled trial
Ret Pig 1993 No published data on age-related macular degeneration. No response from author
Rodriguez-Carmona 2006 No AMD outcomes
SAINTS Study on people with AMD
SCPS 1989 No data on age-related macular degeneration collected
SECURE No published data on age-related macular degeneration. No response from author
Shandong 1998 No data on age-related macular degeneration collected
Sharma 1989 No published data on age-related macular degeneration. No response from author
Steiner 1995 No published data on age-related macular degeneration. No response from author
SUVIMAX No published data on age-related macular degeneration. No response from author
SWSCPSG No data on age-related macular degeneration collected
Takamatsu 1995 No published data on age-related macular degeneration. No response from author
Tomeo 1995 No published data on age-related macular degeneration. No response from author
Tsubono 1997 No data on age-related macular degeneration collected
WAFACS Reported on folic acid, pyridoxine and cyanocobalamin combination treatment
Wahlqvist 1994 No data on age-related macular degeneration collected
Wong 2010 Participants had geographic atrophy
32Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Wright 1985 No published data on age-related macular degeneration. No response from author
Yu 1991 No published data on age-related macular degeneration. No response from author
YUNNAN No published data on age-related macular degeneration. No response from author
Zaridze 1993 No published data on age-related macular degeneration. No response from author
AMD: age-related macular degeneration
Characteristics of ongoing studies [ordered by study ID]
AREDS2
Trial name or title Age-Related EyeDisease Study 2 (AREDS2): amulti-center, randomized trial of lutein, zeaxanthin and omega-
3 long-chain polyunsaturated fatty acids (docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA]) in
age-related macular degeneration
Methods AREDS2 is a multi-centre randomised trial of approximately 4200 participants, designed to assess the effects
of oral supplementation of high doses ofmacular xanthophylls (lutein and zeaxanthin) and omega-3 LCPUFAs
(DHA and EPA) for the treatment of AMD and cataract. AREDS2 was designed to evaluate the effects of
high supplemental doses of lutein and zeaxanthin and omega-3 LCPUFAs on the development of advanced
AMD. The study enrolled participants aged 50 to 85 years, with sufficiently clear ocular media to allow
accurate assessment of AMD from fundus photographs. All participants are offered additional treatment with
the original AREDS formulation (now considered standard of care) and 3 variations of this formula. These
are: (1) no beta-carotene; (2) lower amounts of zinc; and (3) no beta-carotene and lower amounts of zinc.
Eligible participants are followed for a minimum of 5 years
Participants Participants were enrolled on the basis of the AREDS Simplified Severity Scale for defining risk categories for
development of advanced age-related macular degeneration
Interventions 10 mg lutein and 2 mg zeaxanthin (1 tablet)
350 mg DHA and 650 mg EPA (2 soft-gel capsules)
Factorial design, 3 arms (no arm with placebo for both)
Outcomes Primary outcome measures:
Progression to advanced AMD in people at moderate to high risk for progression
Secondary outcome measures:
Progression to moderate vision loss
Adverse events
Progression of lens opacity or incidence of cataract surgery
Effect of study supplements on cognitive function
Effect of DHA/EPA on cardiovascular morbidity and mortality
Starting date 2006
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AREDS2 (Continued)
Contact information See: http://clinicaltrials.gov/show/NCT00345176
Notes -
LIMPIA
Trial name or title Lutein influence on macula of persons issued from AMD parents
Methods Multicentre, double-masked, randomised clinical trial of supplementation with ’Nutrof Total’ (lutein and
zeaxanthin) versus placebo
Participants People at high genetic risk for AMD because their parents had AMD. Age 40 to 70 years
Interventions Nutrof Total or placebo
Outcomes Primary outcome measure:
Macular pigment density at 6 months after supplementation
Secondary outcome measures:
Best corrected visual acuity 12 months
Cognitive ability 12 months
Plasma fatty acids 12 months
Macular pigment density during supplementation and after stopping supplementation
Starting date -
Contact information Jean-Francois Korobelnik
jean-francois.korobelnik@chu-bordeaux.fr
Notes http://clinicaltrials.gov/show/NCT01269697
PHS II
Trial name or title Physician’s Health Study II
Methods Randomised controlled trial
Participants 15,000 physicians aged 55 or older
Interventions 2 x 2 x 2 x 2 factorial design
Alternate day beta-carotene, alternate day vitamin E, daily vitamin C and a daily multivitamin
Outcomes Age-related macular degeneration: reported diagnosis followed up by contact with treating ophthalmologist/
optometrist
Starting date -
Contact information -
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PHS II (Continued)
Notes -
SELECT
Trial name or title Selenium and Vitamin E Cancer Prevention Trial (SELECT) for prostate cancer
Methods This is a randomised, double-masked, multi-centre study. Participants are randomised to one of 4 prevention
arms:
Arm I: participants receive 2 different oral placebos once daily
Arm II: participants receive oral selenium and oral placebo once daily
Arm III: participants receive oral vitamin E and oral placebo once daily
Arm IV: participants receive oral selenium and oral vitamin E once daily
Treatment continues for 7 to 12 years in the absence of unacceptable toxicity or diagnosis of prostate cancer
Quality of life is assessed at baseline and then at 1, 3, 5 and 7 years
Participants are followed annually
Participants Healthy male volunteers. A total of 32,400 participants (8100 per prevention arm) will be accrued for this
study within 5 years
Interventions Dietary supplement: selenium
Dietary supplement: vitamin E
Outcomes Primary outcome measures:
Effect on the clinical incidence of cancer
Effect on cancer-free survival, overall survival and serious cardiovascular events
Quality of life
Association of biological molecular markers with cancer risk
Relationship between effects on cancer risk and genetic factors
Effects in terms of intake of other nutrients, foods and dietary supplements
Effect of other dietary nutrients and dietary patterns on cancer risk
Effects on the reduction of Alzheimer’s disease incidence
Reduction in the risk of age-related macular degeneration or cataract
Starting date July 2001
Contact information -
Notes http://clinicaltrials.gov/show/NCT00006392
WACS
Trial name or title Women’s Antioxidant Cardiovascular Study
Methods -
Participants 8171 female health professionals aged 40 plus with pre-existing cardiovascular disease (CVD) or high risk for
developing CVD
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WACS (Continued)
Interventions 2 x 2 x 2 x 2 factorial design:
Vitamin E (600 IU on alternate days)
Vitamin C (500 mg daily)
Beta-carotene (5 mg on alternate days)
Combination of folate (800 mg daily), vitamin B6 (25 mg daily) and vitamin B12 (1 mg daily)
Outcomes Self report and review of medical records
Starting date 1993
Contact information -
Notes http://clinicaltrials.gov/show/NCT00000541
AMD: age-related macular degeneration
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D A T A A N D A N A L Y S E S
Comparison 1. Any antioxidant versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 AMD 4 62520 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.89, 1.08]
2 Advanced AMD 4 62520 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.80, 1.39]
Comparison 2. Alpha-tocopherol versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 AMD 3 40887 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.85, 1.09]
2 Advanced AMD 3 40887 Risk Ratio (M-H, Fixed, 95% CI) 1.34 [0.84, 2.14]
Comparison 3. Beta-carotene versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 AMD 2 21589 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.89, 1.19]
2 Advanced AMD 2 21589 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.69, 1.36]
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Analysis 1.1. Comparison 1 Any antioxidant versus placebo, Outcome 1 AMD.
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 1 Any antioxidant versus placebo
Outcome: 1 AMD
Study or subgroup Antioxidant Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ATBC 216/728 53/213 10.8 % 1.19 [ 0.92, 1.54 ]
PHS I 275/10585 274/10557 36.1 % 1.00 [ 0.85, 1.18 ]
VECAT 92/504 92/512 12.0 % 1.02 [ 0.78, 1.32 ]
WHS 280/19697 313/19724 41.1 % 0.90 [ 0.76, 1.05 ]
Total (95% CI) 31514 31006 100.0 % 0.98 [ 0.89, 1.08 ]
Total events: 863 (Antioxidant), 732 (Placebo)
Heterogeneity: Chi2 = 3.55, df = 3 (P = 0.31); I2 =16%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.2. Comparison 1 Any antioxidant versus placebo, Outcome 2 Advanced AMD.
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 1 Any antioxidant versus placebo
Outcome: 2 Advanced AMD
Study or subgroup Antioxidant Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ATBC 13/728 1/213 1.6 % 3.80 [ 0.50, 28.91 ]
PHS I 63/10585 66/10557 67.7 % 0.95 [ 0.67, 1.34 ]
VECAT 5/504 4/512 4.1 % 1.27 [ 0.34, 4.70 ]
WHS 29/19697 26/19724 26.6 % 1.12 [ 0.66, 1.90 ]
Total (95% CI) 31514 31006 100.0 % 1.05 [ 0.80, 1.39 ]
Total events: 110 (Antioxidant), 97 (Placebo)
Heterogeneity: Chi2 = 2.00, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Alpha-tocopherol versus placebo, Outcome 1 AMD.
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 2 Alpha-tocopherol versus placebo
Outcome: 1 AMD
Study or subgroup Alpha-tocopherol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ATBC 75/237 53/213 12.1 % 1.27 [ 0.94, 1.72 ]
VECAT 92/504 92/512 19.8 % 1.02 [ 0.78, 1.32 ]
WHS 280/19697 313/19724 68.0 % 0.90 [ 0.76, 1.05 ]
Total (95% CI) 20438 20449 100.0 % 0.97 [ 0.85, 1.09 ]
Total events: 447 (Alpha-tocopherol), 458 (Placebo)
Heterogeneity: Chi2 = 4.25, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Alpha-tocopherol versus placebo, Outcome 2 Advanced AMD.
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 2 Alpha-tocopherol versus placebo
Outcome: 2 Advanced AMD
Study or subgroup Alpha-tocopherol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ATBC 8/237 1/213 3.4 % 7.19 [ 0.91, 57.01 ]
VECAT 5/504 4/512 12.8 % 1.27 [ 0.34, 4.70 ]
WHS 29/19697 26/19724 83.8 % 1.12 [ 0.66, 1.90 ]
Total (95% CI) 20438 20449 100.0 % 1.34 [ 0.84, 2.14 ]
Total events: 42 (Alpha-tocopherol), 31 (Placebo)
Heterogeneity: Chi2 = 3.00, df = 2 (P = 0.22); I2 =33%
Test for overall effect: Z = 1.24 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Beta-carotene versus placebo, Outcome 1 AMD.
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 3 Beta-carotene versus placebo
Outcome: 1 AMD
Study or subgroup Beta-carotene Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ATBC 68/234 53/213 16.8 % 1.17 [ 0.86, 1.59 ]
PHS I 275/10585 274/10557 83.2 % 1.00 [ 0.85, 1.18 ]
Total (95% CI) 10819 10770 100.0 % 1.03 [ 0.89, 1.19 ]
Total events: 343 (Beta-carotene), 327 (Placebo)
Heterogeneity: Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Beta-carotene versus placebo, Outcome 2 Advanced AMD.
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 3 Beta-carotene versus placebo
Outcome: 2 Advanced AMD
Study or subgroup Beta-carotene Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ATBC 2/234 1/213 1.6 % 1.82 [ 0.17, 19.93 ]
PHS I 63/10585 66/10557 98.4 % 0.95 [ 0.67, 1.34 ]
Total (95% CI) 10819 10770 100.0 % 0.97 [ 0.69, 1.36 ]
Total events: 65 (Beta-carotene), 67 (Placebo)
Heterogeneity: Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Macular Degeneration
#2 MeSH descriptor Retinal Degeneration
#3 MeSH descriptor Retinal Neovascularization
#4 MeSH descriptor Choroidal Neovascularization
#5 MeSH descriptor Macula Lutea
#6 macula* near lutea*
#7 (macula* or retina* or choroid*) near/4 degenerat*
#8 (macula* or retina* or choroid*) near/4 neovascul*
#9 maculopath*
#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)
#11 MeSH descriptor Vitamins
#12 vitamin*
#13 MeSH descriptor Vitamin A
#14 retinol*
#15 MeSH descriptor beta Carotene
#16 caroten*
#17 MeSH descriptor Ascorbic Acid
#18 ascorbic next acid
#19 MeSH descriptor Vitamin E
#20 MeSH descriptor alpha-Tocopherol
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#21 alpha tocopherol*
#22 MeSH descriptor Vitamin B 12
#23 cobalamin*
#24 MeSH descriptor Antioxidants
#25 antioxidant* or anti oxidant*
#26 MeSH descriptor Carotenoids
#27 carotenoid*
#28 MeSH descriptor Zinc
#29 zinc*
#30 MeSH descriptor Riboflavin
#31 riboflavin*
#32 MeSH descriptor Selenium
#33 selenium*
#34 MeSH descriptor Lutein
#35 lutein*
#36 MeSH descriptor Xanthophylls
#37 xanthophyll*
#38 zeaxanthin*
#39 (#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24)
#40 (#25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38)
#41 (#39 OR #40)
#42 (#10 AND #41)
Appendix 2. MEDLINE (OvidSP) search strategy
1. exp clinical trial/ [publication type]
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp macular degeneration/
14. exp retinal degeneration/
15. exp retinal neovascularization/
16. exp choroidal neovascularization/
17. exp macula lutea/
18. maculopath$.tw.
19. ((macul$ or retina$ or choroid$) adj3 degener$).tw.
20. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
21. (macula$ adj2 lutea).tw.
22. or/13-21
23. exp vitamins/
24. exp vitamin A/
25. vitamin A.tw.
26. retinol$.tw.
27. exp beta carotene/
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28. caroten$.tw.
29. exp ascorbic acid/
30. ascorbic acid$.tw.
31. vitamin C.tw.
32. exp Vitamin E/
33. exp alpha tocopherol/
34. alpha?tocopherol$.tw.
35. alpha tocopherol$.tw.
36. vitamin E.tw.
37. exp Vitamin B12/
38. vitamin B12.tw.
39. cobalamin$.tw.
40. exp antioxidants/
41. ((antioxidant$ or anti) adj1 oxidant$).tw.
42. exp carotenoids/
43. carotenoid$.tw.
44. exp zinc/
45. zinc$.tw.
46. exp riboflavin/
47. riboflavin$.tw.
48. exp selenium/
49. selenium$.tw.
50. exp lutein/
51. lutein$.tw.
52. exp xanthophylls/
53. xanthophyll.tw.
54. zeaxanthin$.tw.
55. or/23-54
56. 22 and 55
57. 12 and 56
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville (Glanville 2006).
Appendix 3. EMBASE (OvidSP) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
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19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp retina macula degeneration/
34. exp retina degeneration/
35. exp retina neovascularization/
36. exp subretinal neovascularization/
37. maculopath$.tw.
38. ((macul$ or retina$ or choroid$) adj3 degener$).tw.
39. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
40. exp retina macula lutea/
41. (macula$ adj2 lutea$).tw.
42. or/33-41
43. exp vitamins/
44. exp Retinol/
45. vitamin A.tw.
46. retinol$.tw.
47. exp beta carotene/
48. caroten$.tw.
49. exp ascorbic acid/
50. ascorbic acid$.tw.
51. vitamin C.tw.
52. exp alpha tocopherol/
53. alpha?tocopherol$.tw.
54. alpha tocopherol$.tw.
55. vitamin E.tw.
56. vitamin B12.tw.
57. exp cyanocobalamin/
58. cobalamin$.tw.
59. exp antioxidants/
60. ((antioxidant$ or anti) adj1 oxidant$).tw.
61. exp carotenoid/
62. exp zinc/
63. zinc$.tw.
64. exp riboflavin/
65. riboflavin$.tw.
66. exp selenium/
67. selenium$.tw.
68. exp zeaxanthin/
69. zeaxanthin$.tw.
70. lutein$.tw.
71. xanthophyll.tw.
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72. or/43-71
73. 42 and 72
74. 32 and 73
Appendix 4. AMED (OvidSP) search strategy
1. exp eye disease/
2. exp vision disorders/
3. exp retinal disease/
4. maculopath$.tw.
5. ((macul$ or retina$ or choroid$) adj3 degenerat$).tw.
6. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
7. or/1-6
8. exp vitamins/
9. vitamin A.tw.
10. retinol$.tw.
11. exp carotenoids/
12. caroten$.tw.
13. exp ascorbic acid/
14. ascorbic acid$.tw.
15. vitamin C.tw.
16. vitamin E.tw.
17. alpha tocopherol$.tw.
18. vitamin B12.tw.
19. cobalamin$.tw.
20. exp antioxidants/
21. ((antioxidant$ or anti) adj1 oxidant$).tw.
22. zinc/
23. zinc$.tw.
24. riboflavin$.tw.
25. selenium/
26. selenium$.tw.
27. lutein$.tw.
28. xanthophylls.tw.
29. zeaxanthin$.tw.
30. or/8-29
31. 7 and 30
Appendix 5. Open Grey search strategy
macular degeneration AND antioxidant
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Appendix 6. metaRegister of Controlled Trials search strategy
(macular degeneration) AND (antioxidant or vitamin or carotene or selenium or tocopherol)
Appendix 7. ClinicalTrials.gov search strategy
(Macular Degeneration) AND (Antioxidant OR Vitamin OR Carotene OR Selenium OR Tocopherol)
Appendix 8. ICTRP search strategy
Macular Degeneration = Condition AND Antioxidant OR Vitamin OR Carotene OR Selenium OR Tocopherol = Intervention
Appendix 9. MEDLINE (OvidSP) adverse effects search strategy
1. exp retinal degeneration/
2. retinal neovascularization/
3. choroidal neovascularization/
4. exp macula lutea/
5. (macula$ adj2 lutea).tw.
6. ((macul$ or retina$ or choroid$) adj4 degener$).tw.
7. ((macul$ or retina$ or choroid$) adj4 neovasc$).tw.
8. (AMD or ARMD or CNV).tw.
9. maculopath$.tw.
10. or/1-9
11. exp vitamins/
12. vitamin A.tw.
13. retinol$.tw.
14. (caroten$ or betacaroten$).tw.
15. ascorbic acid$.tw.
16. vitamin C.tw.
17. alpha?tocopherol$.tw.
18. alpha tocopherol$.tw.
19. vitamin E.tw.
20. ((antioxidant$ or anti) adj1 oxidant$).tw.
21. zinc/
22. zinc$.tw.
23. or/11-22
24. 10 and 23
25. ae.fs.
26. 24 and 25
27. limit 26 to (meta analysis or randomized controlled trial or “review”)
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